baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Cellectis SA/ FR0010425595 /

6/6/2024 9:30:21 AM	Chg. -0.070	Volume	Bid9:37:29 AM	Ask9:37:29 AM	High	Low
2.340EUR	-2.90%	13,675 Turnover: 32,260.080	2.345Bid Size: 750	2.360Ask Size: 2,000	2.390	2.340

GlobeNewswire 6/4 Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients wi...

GlobeNewswire 5/29 Cellectis’ Annual Shareholders General Meeting to be Held on June 28, 2024

GlobeNewswire 5/28 Cellectis Reports Financial Results for First Quarter 2024

GlobeNewswire 5/27 Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024

GlobeNewswire 5/13 Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

GlobeNewswire 5/9 Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire 5/6 Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

GlobeNewswire 5/2 Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

GlobeNewswire 4/29 Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

GlobeNewswire 4/26 Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advan...

GlobeNewswire 4/22 Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene...

GlobeNewswire 4/10 Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Dis...

GlobeNewswire 4/8 Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and...

GlobeNewswire 3/14 Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updat...

GlobeNewswire 1/16 Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agre...

GlobeNewswire 1/4 Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro D...

GlobeNewswire 1/4 Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, ...

GlobeNewswire 12/22/2023 Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

GlobeNewswire 12/9/2023 Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-6...

GlobeNewswire 12/5/2023 Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actio...

GlobeNewswire 11/17/2023 Cellectis’ Shareholders Meeting to be Held on December 22, 2023

GlobeNewswire 11/15/2023 Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

GlobeNewswire 11/6/2023 Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

GlobeNewswire 11/3/2023 Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Target...

GlobeNewswire 11/3/2023 Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies a...

Cellectis SA/ FR0010425595 /

If you wish to receive reply to your feedback, please provide your email address.